Clinical and Economic Outcomes of Olanzapine Compared With Haloperidol for Schizophrenia
- 1 January 1999
- journal article
- clinical trial
- Published by Springer Nature in PharmacoEconomics
- Vol. 15 (5) , 469-480
- https://doi.org/10.2165/00019053-199915050-00005
Abstract
No abstract availableKeywords
This publication has 41 references indexed in Scilit:
- Standard olanzapine versus placebo and ineffective-dose olanzapine in the maintenance treatment of schizophreniaPsychiatric Services, 1997
- Pharmacoeconomics of antipsychotic drug therapy.1996
- Motor and mental aspects of extrapyramidal syndromes.1995
- Treatment of schizophreniaThe Lancet, 1995
- Conventional Antipsychotic Medications for SchizophreniaSchizophrenia Bulletin, 1995
- Savings in Hospital Bed-Days Related to Treatment With ClozapinePsychiatric Services, 1994
- Cost effectiveness of clozapine in neuroleptic-resistant schizophreniaAmerican Journal of Psychiatry, 1993
- The Costs of Schizophrenia: Assessing the BurdenPsychiatric Clinics of North America, 1993
- Clozapine's cost-benefits.1991
- Cost-Effectiveness of Clozapine for Treatment-Resistant Schizophrenic PatientsPsychiatric Services, 1990